Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.17 EUR
Change Today +0.009 / 0.78%
Volume 0.0
As of 5:17 AM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - €1.51
52 Week Low
10/14/15 - €0.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. The company’s lead immunotherapy candidate, bavituximab, which is in Phase III development stage for the treatment of previously-treated non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. It is also involved in the development of molecular imaging agent, 124I-PGN650, which is in exploratory clinical trial for the imaging of various solid tumor types. The company provides current good manufacturing practice services from cell line development to commercial biomanufacturing for its third-party customers. It has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA.; and collaboration agreement with AstraZeneca PLC for immuno-oncology combination clinical trial. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

211 Employees
Last Reported Date: 07/14/15
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $517.2K
Chief Financial Officer
Total Annual Compensation: $388.0K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $346.7K
Head of Clinical & Regulatory Affairs and Vic...
Total Annual Compensation: $298.9K
Vice President of Intellectual Property
Total Annual Compensation: $319.9K
Compensation as of Fiscal Year 2015.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals, Inc. Announces Results from Multiple New Preclinical Studies

Peregrine Pharmaceuticals, Inc. announced results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma. Additionally, the company announced preliminary results for a new clinical test specifically designed to illustrate how bavituximab, the company's investigational phosphatidylserine (PS)-signaling pathway inhibitor, modulates immune responses in the tumor microenvironment. The positive data presented at SITC with regard to combinations of bavituximab and checkpoint inhibitors further support belief that bavituximab has the potential to be a critical component of innovative combination cancer immunotherapies. Bavituximab is an investigational immunotherapy designed to assist the body's immune system by targeting and modulating the activity of phosphatidylserine (PS), a highly immune-suppressive signaling molecule expressed broadly on the surface of cells in the tumor microenvironment. Peregrine's PS signaling pathway inhibitor candidates, including bavituximab, reverse the immunosuppressive environment that many tumors establish in order to proliferate, while also fighting cancer by activating immune cells that target and fight cancer. The preclinical equivalent of bavituximab, ch1N11, is used in animal model studies as a guide for clinical development.

Peregrine Pharmaceuticals, Inc. Approves Amendment to its Restated Certificate of Incorporation

At the Annual Meeting, Peregrine Pharmaceuticals, Inc.'s stockholders approved an amendment to the company's restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the company's common stock, par value $0.001 per share, from 325,000,000 shares to 500,000,000 shares. The Certificate of Amendment became effective upon filing with the Secretary of State of the State of Delaware on October 15, 2015.

AstraXeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase Ii Lung Cancer Combination Clinical Trial

Peregrine Pharmaceuticals, Inc. announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine. As part of the Phase II bavituximab and durvalumab combination trial, patients will be evaluated retrospectively for the correlation between their PD-L1 levels and clinical outcomes. This new study builds on the non-exclusive collaboration initiated between the companies in August 2015 to conduct a Phase I/Ib basket linical trial evaluating the combination of bavituximab and durvalumab with chemotherapy in multiple solid tumors. Bavituximab and durvalumab are investigational immunotherapies with different mechanisms that assist the body's mmune system in fighting cancer. Bavituximab targets and modulates the activity of phosphatidylserine, a highly immune-suppressive molecule expressed broadly on the surface of cells in the tumor microenvironment. In pre-clinical and translational clinical studies, the treatment increases activated T-cells in tumors and fights cancer by reversing the immunosuppressive environment that many tumors establish in order to proliferate. Durvalumab is a monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. Preclinical data have demonstrated that combining the enhanced T-cell mediated anti-tumor activity of bavituximab with checkpoint inhibitors, like PD-L1 antibodies, prolong the ability of tumor-specific T-cells to continue attacking the tumor. Bavituximab is an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS). Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab, the lead compound in Peregrine's immuno-oncology development program, blocks PS to remove this immunosuppressive signal and sends an alternate immune activating signal. Targeting PS with bavituximab has been shown to shift the functions of mmune cells in tumors, resulting in robust anti-tumor immune responses. Durvalumab is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. Durvalumab blocks these signals, countering the tumor's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.17 EUR +0.009

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genocea Biosciences Inc $6.18 USD +0.02
GenVec Inc $1.71 USD -0.01
Inovio Pharmaceuticals Inc $7.23 USD +0.16
Progenics Pharmaceuticals Inc $6.99 USD +0.31
Vical Inc $0.46 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PEREGRINE PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at